ABSTRACT
Background Posttraumatic stress disorder (PTSD) is triggered by environmental stressors. Empathy may predispose an individual to respond to life events differently if high empathizers are emotionally more sensitive to trauma. For the first time, we test this hypothesis at the genetic level.
Methods We applied polygenic scoring (PGS) to investigate the shared genetics linking empathy (measured using the Empathy Quotient (EQ), a self-report measure of empathy; N=46,861) and PTSD symptom severity (measured using the 6-item PTSD Checklist 6-item (PCL-6)) in the UK Biobank (N=126,219). Follow-up analyses were performed in the context of (1) experiencing any of 16 potential traumas, (2) the total number of traumas endorsed, and (3) the context of trauma. Autism, depression, generalized anxiety, and PCL-17 PGS were included as covariates to verify the specificity of the effect.
Results EQPGS associated with PCL-6 (R2=0.012%, P=9.35×10−5). This effect remained significant after accounting for autism, depression, PTSD, and anxiety PGS but was observed only in those who endorsed experiencing at least one traumatic event. EQPGS showed the strongest effect on PCL-6 (β=2.32, s.e.=0.762, P=0.002) among those who endorsed childhood neglect/abuse (felt hated as a child). In the highest EQPGS decile, feeling hated as a child was associated with lower odds of healthy adulthood interpersonal relationships (OR=0.623, 95%CI 0.443-0.885) but this association was not seen in the lowest EQPGS decile.
Conclusions A genetic predisposition to higher empathy, which may index greater emotional sensitivity, predisposes an individual to more severe PTSD symptoms, specifically in the presence of early negative life events.
Competing Interest Statement
Dr. Gelernter is named as an inventor on PCT patent application #15/878,640 entitled: Genotype-guided dosing of opioid agonists, filed January 24, 2018. Dr. Stein is paid for his editorial work on the journals Biological Psychiatry and Depression and Anxiety, and the health professional reference Up-To-Date; he has also in the past 3 years received consulting income from Actelion, Acadia Pharmaceuticals, Aptinyx, Bionomics, BioXcel Therapeutics, Clexio, EmpowerPharm, GW Pharmaceuticals, Janssen, Jazz Pharmaceuticals, and Roche/Genentech, and has stock options in Oxeia Biopharmaceuticals and Epivario. Drs. Polimanti and Gelernter are paid for their editorial work on the journal Complex Psychiatry. Dr. Krystal reports compensation as the Editor of Biological Psychiatry. He also serves on the Scientific Advisory Boards for Bioasis Technologies, Inc., Biohaven Pharmaceuticals, BioXcel Therapeutics, Inc. (Clinical Advisory Board), Cadent Therapeutics (Clinical Advisory Board), PsychoGenics, Inc, Stanley Center for Psychiatric research at the Broad Institute of MIT and Harvard and the Lohocla Research Corporation. He owns stock in ArRETT Neuroscience, Inc., Biohaven Pharmaceuticals, Sage Pharmaceuticals, and Spring Care, Inc. and stock options in Biohaven Pharmaceuticals Medical Sciences, BlackThorn Therapeutics, Inc. and Storm Biosciences, Inc. He is a co-inventor on multiple patents as listed below: (1) Seibyl JP, Krystal JH, Charney DS. Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. US Patent #:5,447,948.September 5, 1995, (2) Vladimir, Coric, Krystal, John H, Sanacora, Gerard: Glutamate Modulating Agents in the Treatment of Mental Disorders US Patent No. 8,778,979 B2 Patent Issue Date: July 15, 2014. US Patent Application No. 15/695,164: Filing Date: 09/05/2017, (3) Charney D, Krystal JH, Manji H, Matthew S, Zarate C.: Intranasal Administration of Ketamine to Treat Depression United States Application No. 14/197,767 filed on March 5, 2014; United States application or Patent Cooperation Treaty (PCT) International application No. 14/306,382 filed on June 17, 2014, (4): Zarate, C, Charney, DS, Manji, HK, Mathew, Sanjay J, Krystal, JH, Department of Veterans Affairs: Methods for Treating Suicidal Ideation, Patent Application No. 14/197.767 filed on March 5, 2014 by Yale University Office of Cooperative Research, (5) Arias A, Petrakis I, Krystal JH.: Composition and methods to treat addiction. Provisional Use Patent Application no.61/973/961. April 2, 2014. Filed by Yale University Office of Cooperative Research, (6) Chekroud, A., Gueorguieva, R., & Krystal, JH.: Treatment Selection for Major Depressive Disorder [filing date 3rd June 2016, USPTO docket number Y0087.70116US00]. Provisional patent submission by Yale University, (7) Gihyun, Yoon, Petrakis I, Krystal JH: Compounds, Compositions and Methods for Treating or Preventing Depression and Other Diseases. U. S. Provisional Patent Application No. 62/444,552, filed on January 10, 2017 by Yale University Office of Cooperative Research OCR 7088 US01, (8) Abdallah, C, Krystal, JH, Duman, R, Sanacora, G. Combination Therapy for Treating or Preventing Depression or Other Mood Diseases. U.S. Provisional Patent Application No. 047162-7177P1 (00754) filed on August 20, 2018 by Yale University Office of Cooperative Research OCR 7451 US01. The other authors have no competing interests to disclose.
Funding Statement
This study was supported by National Institutes of Health (R21 DC018098, R33 DA047527, and F32 MH122058) and the National Center for PTSD of the U.S. Department of Veterans Affairs. VW is funded by St. Catharine's College, Cambridge. SBC was funded by grants from the Medical Research Council, the Wellcome Trust, the Autism Research Trust, the Templeton World Charity Foundation. SBC also received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 777394. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI. His research was also supported by the National Institute of Health Research (NIHR) Applied Research Collaboration East of England (ARC EoE) programme. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study is exempt from Yale IRB approval because it uses previously collected and de-identified information.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used to generate figures for this study are provided as Supplementary Material. This research has been conducted using the UK Biobank Resource (application reference no. 58146) and is available to bona fide researchers through approved access. GWAS summary statistics are available for download from several repositories: MVP (dbGAP study accession phs001672.v5.p1)and PGC.
